ESBATech is a drug discovery and development company focusing on therapeutic applications of its proprietary antibody fragments derived from fully human antibody fragment scaffolds. ESBATech's antibody fragments have high stability and production yield compared to conventional antibody fragments. This enables new therapeutic applications and reduces production costs. The company has several programs in pre-clinical and clinical development.
Sold to Novartis in 2009